Oncotarget

Research Papers:

The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells

Rui Wang, Yumei Li, Yueyue Hou, Qingling Yang, Sulian Chen, Xi Wang, Zishu Wang, Yan Yang, Changjie Chen, Zhiwei Wang and Qiong Wu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:7000-7010. https://doi.org/10.18632/oncotarget.3193

Metrics: PDF 1572 views  |   HTML 1741 views  |   ?  


Abstract

Rui Wang1, Yumei Li1, Yueyue Hou1, Qingling Yang2, Sulian Chen2, Xi Wang3, Zishu Wang1, Yan Yang1, Changjie Chen2, Zhiwei Wang4, Qiong Wu1

1Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

2Department of Biochemistry and Molecular Biology, Bengbu Medical College, Anhui, China

3Department of Oncology, The 117th Hospital of PLA, Hangzhou, China

4The Cyrus Tang Hematology Center and Collaborative Innovation Center of Hematology, Jiangsu Institute of Hematology, the First Affiliated Hospital, Soochow University, Suzhou, China

Correspondence to:

Qiong Wu, e-mail: qiongwu68@outlook.com

Zhiwei Wang, e-mail: zwang6@bidmc.harvard.edu

Keywords: Hepatocellular carcinoma, EMT, PDGF-D, miR-106a, Twist

Received: December 16, 2014     Accepted: January 23, 2015     Published: February 11, 2015

ABSTRACT

Emerging evidence demonstrates that platelet-derived growth factor-D (PDGF-D) plays a critical role in epithelial-mesenchymal transition (EMT) and drug resistance in hepatocellular carcinoma (HCC) cells. However, the underlying mechanism has not been fully elucidated. The objective is to explore the molecular mechanism of PDGF-D-mediated EMT in drug resistance HCC cells. To achieve our goal, we used multiple approaches including Western blotting, real-time RT-PCR, wound healing assay, invasion assay, luciferase activity assay, transfection, and immunohistochemistry. We found that PDGF-D is highly expressed in gemcitabine-resistant (GR) HCC cells. Moreover, PDGF-D markedly inhibited miR-106a expression and subsequently upregulated Twist1 expression. Notably, PDGF-D expression was associated with miR-106a and Twist1 in HCC patients. Our findings provide a possible molecular mechanism for understanding GR chemoresistance in HCC cells. Therefore, inactivation of PDGF-D/Twist or activation of miR-106a could be a novel strategy for the treatment of HCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3193